Growth through acquisition has been an attractive option for many organizations in the pharma cold chain. One recent example is Knipper Health, long known for its marketing services and 3PL operations ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Paying for more iCloud storage is always an option ... You can select “Forever” if you want to delete the messages yourself, or “1 Year” or “30 Days” if you want messages to permanently delete after ...

A new clinical trial led by researchers at the University of North Carolina School of Medicine has revealed that the oral form of semaglutide (GLP-1) significantly reduces the risk of heart ...

The result is "consistent with prior studies of injectable semaglutide and other GLP-1 receptor agonist," but a positive result is still a big deal, said principal investigator Darren K.

Popular prescription weight-loss drugs called GLP-1 receptor agonists are now frequently used by type 1 diabetes patients, despite limited data on the drugs’ safety and effectiveness in this patient ...

That these treatments are helping people curb their eating should be no surprise: that is exactly what they are meant to do, by mimicking the satiety hormone GLP-1 (see “How they work”, below).

For pharma R&D, the expected ROI was 5.9% in 2024, up from 2023’s 4.1%. Of note is the role that GLP-1 therapies played in that increase, with the average return dropping to 3.8% when the drug ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

Data showed no outcome differences based on diabetes status or type of GLP-1 used. The incidence and risk for suicidality and self-harm were low for individuals given glucagon-like peptide-1 ...